Publications scientifiques en 2013

Depuis le 30/04/2024

  1. Chemotherapy and targeted agents for colorectal cancer in a real-life setting anticipate guidelines: the COLCHIC cohort study.
    Smith D, Terrebonne E, Rouyer M, Blanc JF, Breilh D, Pedeboscq S, Le Monies A, Lecomte C, Lassalle R, Moore N, Fourrier-Reglat A.
    Fundam Clin Pharmacol. 2013
  2. Characteristics associated with use of homeopathic drugs for psychiatric symptoms in the general population.
    Grolleau A, Bégaud B Verdoux H.
    Eur Psychiatry. 2013
  3. Methodology for a multinational case-population study on liver toxicity risks with NSAIDs: the Study of Acute Liver Transplant (SALT).
    Gulmez SE, Larrey D, Pageaux GP, Lignot-Maleyran S, de Vries C, Sturkenboom M, Perez-Gutthann S, Bénichou J, Bissoli F, Horsmans Y, Bernuau J, Stricker B, Thorburn D, Blin P, Moore N.
    Eur J Clin Pharmacol. 2013
  4. Harmonization process for the identification of medical events in eight European healthcare databases: the experience from the EU-ADR project.
    Avillach P, Coloma PM, Gini R, Schuemie M, Mougin F, Dufour JC, Mazzaglia G, Giaquinto C, Fornari C, Herings R, Molokhia M, Pedersen L, Fourrier-Réglat A, Fieschi M, Sturkenboom M, van der Lei J, Pariente A, Trifirò G, EU-ADR consortium.
    J Am Med Inform Assoc. 2013
  5. Licensing of antirheumatic drugs: are the EMA and FDA on the same page?
    Bannwarth B, Berdaï D, Kostine M.
    Joint Bone Spine. 2013
  6. Choice of the denominator in case population studies: event rates for registration for liver transplantation after exposure to NSAIDs in the SALT study in France.
    Moore N, Gulmez SE, Larrey D, Pageaux GP, Lignot S, Lassalle R, Jové J, Pariente A, Blin P, Bénichou J, Bégaud B.
    Pharmacoepidemiol Drug Saf. 2013
  7. Design and validation of an automated method to detect known adverse drug reactions in MEDLINE: a contribution from the EU-ADR project.
    Avillach P, Dufour JC, Diallo G, Salvo F, Joubert M, Thiessard F, Mougin F, Trifirò G, Fourrier-Réglat A, Pariente A, Fieschi M.
    J Am Med Inform Assoc. 2013
  8. Acute and sub-chronic (28days) oral toxicity evaluation of hydroethanolic extract of Bridelia ferruginea Benth root bark in male rodent animals.
    Bakoma B, Berke B, Eklu-Gadegbeku K, Agbonon A, Aklikokou K, Gbeassor M, Creppy EE, Moore N.
    Food Chem Toxicol. 2013
  9. Ca2+-Activated K+ Channel-3.1 Blocker TRAM-34 Attenuates Airway Remodeling and Eosinophilia in a Murine Asthma Model.
    Girodet PO, Ozier A, Carvalho G, Ilina O, Ousova O, Gadeau AP, Begueret H, Wulff H, Marthan R, Bradding P, Berger P.
    Am J Respir Cell Mol Biol. 2013
  10. Double blind randomized pilot trial evaluating the efficacy of oral propranolol on infantile hemangiomas in infants less than 4 months of age.
    Léauté-Labrèze C, Dumas de la Roque E, Nacka F, Abouelfath A, Grenier N, Rebola M, Ezzedine K, Moore N.
    Br J Dermatol. 2013
  11. Transplantation for Acute Liver Failure in Patients Exposed to NSAIDs or Paracetamol (Acetaminophen): The Multinational Case-Population SALT Study.
    Gulmez SE, Larrey D, Pageaux GP, Lignot S, Lassalle R, Jove J, Gatta A, McCormick PA, Metselaar HJ, Monteiro E, Thorburn D, Bernal W, Zouboulis-Vafiadis I, de Vries C, Perez-Gutthann S, Sturkenboom M, Bénichou J, Montastruc JL, Horsmans Y, Salvo F, Hamoud F, Micon S, Droz-Perroteau C, Blin P, Moore N.
    Drug Saf. 2013
  12. From in vitro to in vivo: intracellular determination of imatinib and nilotinib may be related with clinical outcome.
    Bouchet S, Dulucq S, Pasquet JM, Lagarde V, Molimard M, Mahon FX.
    Leukemia. 2013
  13. A few clarifications please.
    Moore ND.
    BMJ. 2013
  14. Prescription of Antiepileptics and the Risk of Road Traffic Crash.
    Orriols L, Foubert-Samier A, Gadegbeku B, Delorme B, Tricotel A, Philip P, ... Lagarde E.
    J Clin Pharmacol. 2013
  15. Attitudes and opinion about adverse drug events of women living in a city of south Italy.
    Salvo F, Miroddi M, Alibrandi A, Calapai F, Cafeo V, Mancari F, Gangemi S, Caputi AP, Calapai G.
    Pharmacology. 2013
  16. Is paracetamol hepatotoxic at normal doses?
    Moore ND, Gulmez E, Blin P.
    BMJ. 2013
  17. Aminoglycosides in septic shock: an overview, with specific consideration given to their nephrotoxic risk.
    Boyer A, Gruson D, Bouchet S, Clouzeau B, Hoang-Nam B, Vargas F, Gilles H, Molimard M, Rogues AM, Moore N.
    Drug Saf. 2013
  18. Pharmacovigilance systems in developing countries: an evaluative case study in Burkina Faso.
    Kabore L, Millet P, Fofana S, Berdai D, Adam C, Haramburu F.
    Drug Saf . 2013
  19. Myocardial infarction and individual nonsteroidal anti-inflammatory drugs meta-analysis of observational studies.
    Varas-Lorenzo C, Riera-Guardia N, Calingaert B, Castellsague J, Salvo F, Nicotra F, Sturkenboom M, Perez-Gutthann S.
    Pharmacoepidemiol Drug Saf. 2013
  20. Impact of therapy escalation on ambulatory care costs among patients with type 2 diabetes in France.
    Guelfucci F, Clay E, Aballéa S, Lassalle R, Moore N, Toumi M.
    BMC Endocr Disord. 2013
  21. The past, present and perhaps future of pharmacovigilance: homage to Folke Sjoqvist.
    Moore N.
    Eur J Clin Pharmacol. 2013
  22. A potential event-competition bias in safety signal detection: results from a spontaneous reporting research database in France.
    Salvo F, Leborgne F, Thiessard F, Moore N, Bégaud B, Pariente A.
    Drug Saf. 2013
  23. Dynamic and rapid changes in viral quasispecies by UDPS in chronic hepatitis C patients receiving telaprevir-based therapy.
    Trimoulet P, Pinson P, Papuchon J, Foucher J, Vergniol J, Chermak F, Wittkop L, Castaing N, Merrouche W, Reigadas S, Molimard M, Kann M, Fleury H, de Lédinghen V.
    Antivir Ther. 2013
  24. Causality of Drugs Involved in Acute Liver Failure Leading to Transplantation: Results from the Study of Acute Liver Transplant (SALT).
    Gulmez SE, Moore N, Pageaux GP, Lignot S, Horsmans Y, Stricker B, Bernuau J, Bissoli F, Thorburn D, Montastruc JL, Micon S, Hamoud F, Lassalle R, Jové J, Blin P, Larrey D.
    Drug Saf. 2013
  25. Comparison of three methods (an updated logistic probabilistic method, the Naranjo and Liverpool algorithms) for the evaluation of routine pharmacovigilance case reports using consensual expert judgement as reference.
    Théophile H, André M, Miremont-Salamé G, Arimone Y, Bégaud B.
    Drug Saf. 2013
  26. Observation of the long-term effects of lifestyle intervention during balneotherapy in metabolic syndrome.
    Gin H, Demeaux JL, Grelaud A, Grolleau A, Droz-Perroteau C, Robinson P, Lassalle R, Abouelfath A, Boisseau M, Toussaint C, Moore N.
    Therapie. 2013
  27. Once-daily glycopyrronium via the Breezhaler® device for the treatment of COPD: pharmacological and clinical profile.
    Molimard M, D'Andrea P.
    Expert Rev Clin Pharmacol. 2013
  28. Off-label prescriptions: how to identify them, frame them, announce them and monitor them in practice?
    Le Jeunne C, Billon N, Dandon A; participants of round table N° 3 of Giens XXVIII (th), Berdaï D, Adgibi Y, Bergmann JF, Bordet R, Carpentier A, Cohn E, Courcier S, Girault D, Goni S, Jolliet P, Liard F, Prot-Labarthe S, Simon T, Vernotte C, Westerloppe J.
    Therapie. 2013
  29. Relative risks from case-population data.
    Moore N, Gulmez SE, Blin P, Lassalle R, Jove J, Théophile H, Bégaud B, Larrey D, Bénichou J.
    Epidemiology. 2013
  30. [Drug safety. Why and how? "All drugs are dangerous, some are also useful"]
    Moore N.
    Prog Urol. 2013
  31. [Analyze and use the results of clinical studies in the context of good use. Critical analysis, clinical research and levels of evidence].
    Pariente A.
    Rev Prat. 2013